Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

selpercatinib 2lutetium Lu 177 dotatate 2entrectinib 2cabozantinib 2Fulvestrant 2trametinib 1ribociclib 1repotrectinib 1pralsetinib 1pembrolizumab 1dabrafenib 1copper dotatate CU-64 1belzutifan 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Octreotide 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Alpelisib 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × lutetium Lu 177 dotatate × Endocrine × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed
231 enrolled 16 charts 2 FDA
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡